Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares Under 10b5-1 Plan

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2024, Daniel N. Swisher Jr., a director of Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $5.86 per share.
• Simultaneously, Swisher sold 2,200 shares of common stock at $25.30 per share.
• The transactions were executed under a pre-existing 10b5-1 trading plan.
• Following these transactions, Swisher directly owns 6,750 derivative securities.

Sentiment

Score: 5

Explanation: The document reports routine transactions by a company director under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

Trading activity by company insiders is common and closely monitored. The use of 10b5-1 plans allows insiders to sell shares without being accused of acting on non-public information.

Comparison to Industry Standards

• Corporate insiders frequently use 10b5-1 trading plans to manage their stock holdings, a practice seen across various companies like Pfizer, Apple, and Microsoft.
• The reported transactions are typical for executives managing their personal finances while complying with insider trading regulations.
• The scale of the transaction is small, involving only 2,200 shares, which is not unusual for routine insider trading activities.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders, as they are part of a pre-arranged trading plan and involve a small number of shares.

Key Dates